SequelSEC

Guardant Health, Inc. GH

Services-Medical Laboratories · CIK 0001576280 · Fiscal year ends 1231

Revenue
$982.02M
Fiscal year ended 2025-12-31
Operating income
-$437.25M
Fiscal year ended 2025-12-31
Free cash flow
-$233.07M
Fiscal year ended 2025-12-31

Guardant Health, Inc. (GH) reported revenue of $982.02M and net income of -$416.28M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Guardant Health, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Medical Laboratories.

Income

Guardant Health, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$982.02M$739.02M$563.95M$449.54M$373.65M$286.73M$214.38M$90.64M$49.84M$25.25M
Cost of revenue$349.01M$289.80M$227.05MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profit$633.01M$449.22M$336.90MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$437.25M-$443.59M-$564.72M-$544.38M-$411.00M-$254.95M-$82.37M-$92.94M-$76.61M-$43.85M
Net income-$416.28M-$436.37M-$479.45M-$654.59M-$384.77MUnavailable-$75.65M-$85.06M-$83.22M-$46.14M
Research & development$364.19M$347.75M$367.19M$373.81M$263.22M$149.86M$86.29M$50.71M$25.56M$10.86M
Weighted-average diluted sharesshares 125.37Mshares 122.74Mshares 111.99Mshares 102.18Mshares 101.31Mshares 97.50Mshares 90.60MUnavailableUnavailableUnavailable
Pretax income-$417.54M-$435.09M-$478.76M-$653.45M-$384.47M-$245.90M-$69.72M-$84.22M-$83.21M-$46.13M
Income tax expense-$1.26M$1.28M$685.00K$1.14M$300.00K$379.00K-$1.87M$38.00K$7.00K$6.00K
Diluted EPS$-3.32$-3.56$-4.28$-6.41$-4.00$-2.60$-0.84UnavailableUnavailableUnavailable
Selling, general & administrative$706.07M$545.06M$451.03M$463.78M$398.52M$299.28M$139.73M$89.66M$69.27M$36.11M
General & administrative$211.41M$180.12M$155.80M$163.96M$206.64M$192.77M$61.40M$36.19M$36.78M$9.92M
Selling & marketing$494.66M$364.94M$295.23M$299.83M$191.88M$106.51M$78.34M$53.46M$32.50M$26.19M

Balance

Guardant Health, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Cash & equivalents$378.20M$525.54M$1.13B$141.65M$492.20M$832.98M$143.23M$140.54M$72.28MUnavailable
Total assets$2.01B$1.49B$1.79B$1.61B$2.20B$2.27B$962.54M$587.40M$342.94MUnavailable
Current assets$1.47B$1.06B$1.35B$1.19B$1.11B$1.89B$597.36M$468.99M$242.94MUnavailable
Total liabilities$2.11B$1.63B$1.63B$1.55B$1.56B$916.19M$114.54M$62.45M$34.33MUnavailable
Current liabilities$302.73M$225.58M$205.92M$193.22M$194.69M$66.81M$72.73M$46.94M$19.63MUnavailable
Total equity incl. NCI-$99.31M-$139.65M$158.68M$60.18M$645.00M$1.30B$798.39M$483.15M$308.61M$79.70M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailable$0$57.10M$49.60M$41.80M$0Unavailable
Inventory$85.88M$71.08M$61.95M$51.60M$30.67M$22.72M$15.18M$9.14M$7.29MUnavailable
Accounts receivable$137.85M$110.25M$88.78M$97.26M$97.65M$53.30M$47.99M$35.69M$12.79MUnavailable
Goodwill$77.26M$3.29M$3.29M$3.29M$3.29M$3.29M$3.29M$0UnavailableUnavailable
Long-term debt$1.50B$1.14BUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payable$54.44M$38.55M$51.74M$68.91M$38.52M$7.34M$16.20M$10.64M$5.00MUnavailable

Cash flow

Guardant Health, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Operating cash flow-$184.76M-$239.86M-$324.98M-$309.46M-$209.02M-$103.93M-$47.13M-$72.18M-$72.24M-$36.71M
Capital expenditures$48.31M$35.08M$20.49M$77.46M$75.04M$36.17M$18.72M$20.20M$6.68M$1.77M
Investing cash flow-$627.20M-$261.31M$840.25M$149.82M-$63.16M-$617.09M-$317.57M-$153.03M-$170.42M$26.20M
Financing cash flow$671.13M-$996.00K$477.38M-$189.09M-$66.82M$1.41B$367.30M$293.16M$281.66M$39.84M
Net change in cash-$140.34M-$503.93M$991.74M-$350.34M-$340.69M$689.75M$2.68M$67.95M$39.00MUnavailable
Stock-based compensation$166.22M$140.41M$90.76M$94.68M$151.45M$144.11M$16.95M$6.85M$3.67M$1.97M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchases$45.01M$0$0UnavailableUnavailable$0$0$172.00K$7.22M$100.00K
Depreciation & amortization$39.74M$42.39M$42.88M$35.96M$22.27M$16.06M$11.41M$7.14M$5.21M$3.69M

Derived

Guardant Health, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Free cash flow-$233.07M-$274.94M-$345.46M-$386.92M-$284.05M-$140.10M-$65.85M-$92.39M-$78.92M-$38.48M
Gross margin64.5%60.8%59.7%UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating margin-44.5%-60.0%-100.1%-121.1%-110.0%-88.9%-38.4%-102.5%-153.7%-173.7%
FCF margin-23.7%-37.2%-61.3%-86.1%-76.0%-48.9%-30.7%-101.9%-158.3%-152.4%
SBC / revenue16.9%19.0%16.1%21.1%40.5%50.3%7.9%7.6%7.4%7.8%
Current ratio4.84x4.68x6.54x6.17x5.72x28.27x8.21x9.99x12.38xUnavailable
Revenue YoY growth32.9%31.0%25.5%20.3%30.3%33.8%136.5%81.9%97.4%Unavailable
Net margin-42.4%-59.0%-85.0%-145.6%-103.0%UnavailableUnavailableUnavailable-167.0%-182.7%
R&D / revenue37.1%47.1%65.1%83.2%70.4%52.3%40.3%56.0%51.3%43.0%
CapEx / revenue4.9%4.7%3.6%17.2%20.1%12.6%8.7%22.3%13.4%7.0%
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open GH in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-07-30View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-02-19View SEC filing
10-Q · Filed 2025-10-29View SEC filing
10-Q · Filed 2025-07-30View SEC filing
10-Q · Filed 2025-04-30View SEC filing

Companies in the same industry

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.